Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ReNeuron Group PLC treats first patient in retinitis pigmentosa trial

The procedure involves a single injection of hRPC cells under the retina
ReNeuron Group PLC treats first patient in retinitis pigmentosa trial
RP leads to progressive loss of sight due to photoreceptor cells in the retina becoming damaged and eventually dying.

Stem cell specialist ReNeuron Group PLC (LON:RENE) has treated its first patient in a phaseI/II US trial of its retinitis pigmentosa (RP) cell therapy remedy.

The procedure, involving a single injection of hRPC cells under the retina, was conducted at Massachusetts Eye and Ear in Boston, a teaching affiliate of Harvard Medical School and a specialist in retinal degeneration. The patient was discharged from hospital that day.

RP leads to progressive loss of sight due to photoreceptor cells in the retina becoming damaged and eventually dying. 

ReNeuron’s Human Retinal Progenitor Cells (hRPCs) have shown an ability to protect the host retina from further degeneration and also potentially treat any of the genetic variants of RP.

Fifteen patients will be treated with  hRPC in the trial, the company’s first in the US. The hRPC programme has US fast-track status and Orphan Drug Designation in both the US and Europe.

ReNeuron aims to file for a Phase II/III clinical trial in the second half of 2017 dependent on how this trial goes.  

Olav Hellebo, ReNeuron’s chief executive said:  “Retinal degenerative diseases represent extremely attractive targets for cell therapy approaches and our programme targeting RP benefits from a number of key competitive advantages in terms of the potential mechanisms of action of our hRPC cells and the potential speed of clinical development to market for this programme.

“With the start of this study, we are also delighted to have commenced clinical development activities in the US, a major target market."

PhilW.jpg
Why Invest In ReNeuron Group Plc? Read More Here

Register here to be notified of future RENE Company articles
View full RENE profile

ReNeuron Group Plc Timeline

Related Articles

1-SG02055.jpg
March 22 2016
e-Therapeutics is now targeting partners to accelerate the development of its drug discovery engine and commercialise compounds.
stem-cells.jpg
February 25 2016
Early 2016 looks to be data-rich for stem cell group ReNeuron as it progresses its clinical portfolio on multiple fronts.
Pollen2.jpg
July 13 2016
Updating investors, the company said turnover will be around £48.5mln, representing a rise of 12%, or 19% once the figure is adjusted for currency movements.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.